Access Pharmaceuticals of Dallas Reports First Quarter 2013 Results

Access Pharmaceuticals (ACCP), a growing biopharmaceutical company with a focus on oncology, has released financial results for the first quarter of this year, which ended on March 31, 2o13. The Dallas-based company’s lead product, MuGard, has been approved for sale in the United States and Europe, as well as South Korea and China.

http://bionews-tx.com/news/2013/05/21/access-pharmaceuticals-of-dallas-reports-first-quarter-2013-results/

Austin-Based Vermillion Announces First Quarter 2013 Results and Future Plans

Vermillion, Inc. (VRML) has released financial data pertaining to their first quarter results for 2013; these numbers include the results as of March 31, 2013. The company is based in Austin, Texas, and specializes in molecular diagnostics that focus on women’s health and especially gynecological cancers.

http://bionews-tx.com/news/2013/05/16/austin-based-vermillion-announces-first-quarter-2013-results-and-future-plans/

Opexa Therapeutics Reports First Quarter 2013 Financial Results

Opexa Therapeutics (OPXA), a Woodlands-based biotech company specializing in the development of an innovative immunotherapy using T-cells to treat multiple sclerosis, as of April 30, 2013 has enrolled 48 patients with Secondary Progressive Multiple Sclerosis in a Phase IIb clinical test of the imilecleucel-T, autologous T-Cell Immunotherapy known as Tcelna™.

http://bionews-tx.com/news/2013/05/15/opexa-therapeutics-reports-first-quarter-2013-financial-results/

First Quarter 2013 Results Announced for Orthofix International

Orthofix International N.V., a Texas-based company that produces products used to treat spine and orthopedic conditions, has announced their first quarter financial results for 2013.

http://bionews-tx.com/news/2013/05/09/first-quarter-2013-results-announced-for-orthofix-international/

Austin’s Luminex Corporation Reports Its Q1 2013 Results

It would appear to be good news for Austin-Based Luminex Corporation, who recently reported an increase in revenues, profit margin, a key FDA approval, and a new partnership in their first quarter 2013 results. The company, which develops, manufactures and markets biological diagnostic technologies for the life science industries, continues to report steady growth in its sectors.

http://bionews-tx.com/news/2013/04/30/austins-luminex-corporation-reports-its-q1-2013-results/

"Golden Triangle" Heat Map Illustrates The Value of Top-Rated Organic Search Results

Read about how the "Golden Triangle" Heat Map Illustrates The Value of Top-Rated Organic Search Results

http://www.rcnmarketing.com/golden-triangle-heat-map-illustrates-the-value-of-top-ranked-organic-search-results/